Tumour markers of prognosis in colorectal cancer

Abstract

16 November 2011 This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication

Shown for reading. Its publisher allows quoting it, not republishing it.

References 97

1. 1.

   ASTLER V. B., COLLER F. A. The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg. 1954;139(6):846-852.

   Not in our library10.1097/00000658-195406000-00015

2. 2.

   Amaya H., Tanigawa N., Lu C., Matsumura M., Shimomatsuya T., Horiuchi T., Muraoka R. Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. Cancer Lett. 1997;119(2):227-235.

   Not in our library10.1016/s0304-3835(97)00280-2

3. 3.

   Ambiru S., Miyazaki M., Ito H., Nakagawa K., Shimizu H., Nukui Y., Nozawa S., Okuno A., Yoshitomi H., Nakajima N. A prospective study of prognostic value of type IV collagenase activity in colorectal cancer tissue. Dig Dis Sci. 1997;42(8):1660-1665.

   Not in our library10.1023/a:1018801229372

4. 4.

   Andersen S. N., Løvig T., Breivik J., Lund E., Gaudernack G., Meling G. I., Rognum T. O. K-ras mutations and prognosis in large-bowel carcinomas. Scand J Gastroenterol. 1997;32(1):62-69.

   Not in our library10.3109/00365529709025065

5. 5.

   Apolinario R. M., van der Valk P., de Jong J. S., Deville W., van Ark-Otte J., Dingemans A. M., van Mourik J. C., Postmus P. E., Pinedo H. M., Giaccone G. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol. 1997;15(6):2456-2466.

   Not in our library10.1200/jco.1997.15.6.2456

6. 6.

   Arribas R., Capellà G., Tórtola S., Masramon L., Grizzle W. E., Perucho M., Peinado M. A. Assessment of genomic damage in colorectal cancer by DNA fingerprinting: prognostic applications. J Clin Oncol. 1997;15(10):3230-3240.

   Not in our library10.1200/jco.1997.15.10.3230

7. 7.

   Augenlicht L. H., Wadler S., Corner G., Richards C., Ryan L., Multani A. S., Pathak S., Benson A., Haller D., Heerdt B. G. Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Res. 1997;57(9):1769-1775.

   Not in our library

8. 8.

   Baas I. O., Mulder J. W., Offerhaus G. J., Vogelstein B., Hamilton S. R. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol. 1994;172(1):5-12.

   Not in our library10.1002/path.1711720104

9. 9.

   Baretton G. B., Diebold J., Christoforis G., Vogt M., Müller C., Dopfer K., Schneiderbanger K., Schmidt M., Löhrs U. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Cancer. 1996;77(2):255-264.

   Not in our library10.1002/(sici)1097-0142(19960115)77:2<255::aid-cncr6>3.0.co;2-l

10. 10.

    Baretton G. B., Vogt M., Müller C., Diebold J., Schneiderbanger K., Schmidt M., Löhrs U. Prognostic significance of p53 expression, chromosome 17 copy number, and DNA ploidy in non-metastasized colorectal carcinomas (stages IB and II). Scand J Gastroenterol. 1996;31(5):481-489.

    Not in our library10.3109/00365529609006769

11. 11.

    Bell S. M., Scott N., Cross D., Sagar P., Lewis F. A., Blair G. E., Taylor G. R., Dixon M. F., Quirke P. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology. 1993;104(1):57-64.

    Not in our library10.1016/0016-5085(93)90835-z

12. 12.

    Belluco C., Guillem J. G., Kemeny N., Huang Y., Klimstra D., Berger M. F., Cohen A. M. p53 nuclear protein overexpression in colorectal cancer: a dominant predictor of survival in patients with advanced hepatic metastases. J Clin Oncol. 1996;14(10):2696-2701.

    Not in our library10.1200/jco.1996.14.10.2696

13. 13.

    Benhattar J., Losi L., Chaubert P., Givel J. C., Costa J. Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology. 1993;104(4):1044-1048.

    Not in our library10.1016/0016-5085(93)90272-e

14. 14.

    Bennett M. A., Kay E. W., Mulcahy H., O'flaherty L., O'donoghue D. P., Leader M., Croke D. T. ras and p53 in the prediction of survival in Dukes' stage B colorectal carcinoma. Clin Mol Pathol. 1995;48(6):M310-M315.

    Not in our library10.1136/mp.48.6.m310

15. 15.

    Bhatavdekar J. M., Patel D. D., Ghosh N., Chikhlikar P. R., Trivedi T. I., Suthar T. P., Doctor S. S., Shah N. G., Balar D. B. Coexpression of Bcl-2, c-Myc, and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma. Dis Colon Rectum. 1997;40(7):785-790.

    Not in our library10.1007/bf02055433

16. 16.

    Bosari S., Moneghini L., Graziani D., Lee A. K., Murray J. J., Coggi G., Viale G. bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. Hum Pathol. 1995;26(5):534-540.

    Not in our library10.1016/0046-8177(95)90250-3

17. 17.

    Bosari S., Viale G., Bossi P., Maggioni M., Coggi G., Murray J. J., Lee A. K. Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. J Natl Cancer Inst. 1994;86(9):681-687.

    Not in our library10.1093/jnci/86.9.681

18. 18.

    Bosari S., Viale G. The clinical significance of p53 aberrations in human tumours. Virchows Arch. 1995;427(3):229-241.

    Not in our library10.1007/bf00203389

19. 19.

    Brett M. C., Pickard M., Green B., Howel-Evans A., Smith D., Kinsella A., Poston G. p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer. Eur J Surg Oncol. 1996;22(2):182-185.

    Not in our library10.1016/s0748-7983(96)90827-6

20. 20.

    Chambers A. F., Matrisian L. M. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997;89(17):1260-1270.

    Not in our library10.1093/jnci/89.17.1260

21. 21.

    Cohen A. M., Tremiterra S., Candela F., Thaler H. T., Sigurdson E. R. Prognosis of node-positive colon cancer. Cancer. 1991;67(7):1859-1861.

    Not in our library10.1002/1097-0142(19910401)67:7<1859::aid-cncr2820670707>3.0.co;2-a

22. 22.

    Costa A., Doci R., Mochen C., Bignami P., Faranda A., Gennari L., Silvestrini R. Cell proliferation-related markers in colorectal liver metastases: correlation with patient prognosis. J Clin Oncol. 1997;15(5):2008-2014.

    Not in our library10.1200/jco.1997.15.5.2008

23. 23.

    Cox L. S., Lane D. P. Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. Bioessays. 1995;17(6):501-508.

    Not in our library10.1002/bies.950170606

24. 24.

    Dix B. R., Robbins P., Soong R., Jenner D., House A. K., Iacopetta B. J. The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int J Cancer. 1994;59(6):747-751.

    Not in our library10.1002/ijc.2910590606

25. 25.

    Dorudi S., Hanby A. M., Poulsom R., Northover J., Hart I. R. Level of expression of E-cadherin mRNA in colorectal cancer correlates with clinical outcome. Br J Cancer. 1995;71(3):614-616.

    Not in our library10.1038/bjc.1995.119

26. 26.

    Elnatan J., Goh H. S., Smith D. R. C-KI-RAS activation and the biological behaviour of proximal and distal colonic adenocarcinomas. Eur J Cancer. 1996;32A(3):491-497.

    Not in our library10.1016/0959-8049(95)00567-6

27. 27.

    Fearon E. R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759-767.

    Not in our library10.1016/0092-8674(90)90186-i

28. 28.

    Findlay M. P., Cunningham D., Morgan G., Clinton S., Hardcastle A., Aherne G. W. Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer. 1997;75(6):903-909.

    Not in our library10.1038/bjc.1997.159

29. 29.

    Ganesh S., Sier C. F., Heerding M. M., van Krieken J. H., Griffioen G., Welvaart K., van de Velde C. J., Verheijen J. H., Lamers C. B., Verspaget H. W. Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer. Br J Cancer. 1997;75(12):1793-1801.

    Not in our library10.1038/bjc.1997.306

30. 30.

    Goh H. S., Yao J., Smith D. R. p53 point mutation and survival in colorectal cancer patients. Cancer Res. 1995;55(22):5217-5221.

    Not in our library

31. 31.

    Griffiths L., Stratford I. J. Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy. Br J Cancer. 1997;76(6):689-693.

    Not in our library10.1038/bjc.1997.447

32. 32.

    Hermanek P., Wiebelt H., Staimmer D., Riedl S. Prognostic factors of rectum carcinoma--experience of the German Multicentre Study SGCRC. German Study Group Colo-Rectal Carcinoma. Tumori. 1995;81(3 Suppl):60-64.

    Not in our library

33. 33.

    Hoffmann D., Moore J., Roder D. Trends in survival from colonic cancer: the impact of subspecialization. Aust N Z J Surg. 1997;67(12):842-845.

    Not in our library10.1111/j.1445-2197.1997.tb07608.x

34. 34.

    Jackman A. L., Kelland L. R., Kimbell R., Brown M., Gibson W., Aherne G. W., Hardcastle A., Boyle F. T. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. Br J Cancer. 1995;71(5):914-924.

    Not in our library10.1038/bjc.1995.178

35. 35.

    Jen J., Kim H., Piantadosi S., Liu Z. F., Levitt R. C., Sistonen P., Kinzler K. W., Vogelstein B., Hamilton S. R. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med. 1994;331(4):213-221.

    Not in our library10.1056/nejm199407283310401

36. 36.

    Johnston P. G., Drake J. C., Trepel J., Allegra C. J. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res. 1992;52(16):4306-4312.

    Not in our library

37. 37.

    Johnston P. G., Fisher E. R., Rockette H. E., Fisher B., Wolmark N., Drake J. C., Chabner B. A., Allegra C. J. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol. 1994;12(12):2640-2647.

    Not in our library10.1200/jco.1994.12.12.2640

38. 38.

    Johnston P. G., Lenz H. J., Leichman C. G., Danenberg K. D., Allegra C. J., Danenberg P. V., Leichman L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 1995;55(7):1407-1412.

    Not in our library

39. 39.

    Kapitanović S., Radosević S., Kapitanović M., Andelinović S., Ferencić Z., Tavassoli M., Primorać D., Sonicki Z., Spaventi S., Pavelic K. The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology. 1997;112(4):1103-1113.

    Not in our library10.1016/s0016-5085(97)70120-3

40. 40.

    Kay E. W., Mulcahy H., Walsh C. B., Leader M., O'Donoghue D. Cytoplasmic c-erbB-2 protein expression correlates with survival in Dukes' B colorectal carcinoma. Histopathology. 1994;25(5):455-461.

    Not in our library10.1111/j.1365-2559.1994.tb00007.x

41. 41.

    Kitadai Y., Ellis L. M., Tucker S. L., Greene G. F., Bucana C. D., Cleary K. R., Takahashi Y., Tahara E., Fidler I. J. Multiparametric in situ mRNA hybridization analysis to predict disease recurrence in patients with colon carcinoma. Am J Pathol. 1996;149(5):1541-1551.

    Not in our library

42. 42.

    Kochhar R., Halling K. C., McDonnell S., Schaid D. J., French A. J., O'Connell M. J., Nagorney D. M., Thibodeau S. N. Allelic imbalance and microsatellite instability in resected Duke's D colorectal cancer. Diagn Mol Pathol. 1997;6(2):78-84.

    Not in our library10.1097/00019606-199704000-00002

43. 43.

    Kornmann M., Link K. H., Lenz H. J., Pillasch J., Metzger R., Butzer U., Leder G. H., Weindel M., Safi F., Danenberg K. D. Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. Cancer Lett. 1997;118(1):29-35.

    Not in our library10.1016/s0304-3835(97)00220-6

44. 44.

    Koshida Y., Saegusa M., Okayasu I. Apoptosis, cell proliferation and expression of Bcl-2 and Bax in gastric carcinomas: immunohistochemical and clinicopathological study. Br J Cancer. 1997;75(3):367-373.

    Not in our library10.1038/bjc.1997.60

45. 45.

    Kressner U., Lindmark G., Gerdin B., Påhlman L., Glimelius B. Immunohistological p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer. Anticancer Res. 1996;16(2):951-957.

    Not in our library

46. 46.

    Kumar V., Bustin S. A., McKay I. A. Transforming growth factor alpha. Cell Biol Int. 1995;19(5):373-388.

    Not in our library10.1006/cbir.1995.1083

47. 47.

    Lanza G., Maestri I., Dubini A., Gafa R., Santini A., Ferretti S., Cavazzini L. p53 expression in colorectal cancer: relation to tumor type, DNA ploidy pattern and short-term survival. Am J Clin Pathol. 1996;105(5):604-612.

    Not in our library10.1093/ajcp/105.5.604

48. 48.

    Lawrence D. A. Transforming growth factor-beta: a general review. Eur Cytokine Netw. 1996;7(3):363-374.

    Not in our library

49. 49.

    Leahy D. T., Salman R., Mulcahy H., Sheahan K., O'Donoghue D. P., Parfrey N. A. Prognostic significance of p53 abnormalities in colorectal carcinoma detected by PCR-SSCP and immunohistochemical analysis. J Pathol. 1996;180(4):364-370.

    Not in our library10.1002/(sici)1096-9896(199612)180:4<364::aid-path683>3.0.co;2-0

50. 50.

    Leichman C. G., Lenz H. J., Leichman L., Danenberg K., Baranda J., Groshen S., Boswell W., Metzger R., Tan M., Danenberg P. V. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol. 1997;15(10):3223-3229.

    Not in our library10.1200/jco.1997.15.10.3223

51. 51.

    Loda M., Cukor B., Tam S. W., Lavin P., Fiorentino M., Draetta G. F., Jessup J. M., Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997;3(2):231-234.

    Not in our library10.1038/nm0297-231

52. 52.

    Lowe S. W., Ruley H. E., Jacks T., Housman D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74(6):957-967.

    Not in our library10.1016/0092-8674(93)90719-7

53. 53.

    Manne U., Myers R. B., Moron C., Poczatek R. B., Dillard S., Weiss H., Brown D., Srivastava S., Grizzle W. E. Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int J Cancer. 1997;74(3):346-358.

    Not in our library10.1002/(sici)1097-0215(19970620)74:3<346::aid-ijc19>3.0.co;2-9

54. 54.

    Markowitz S, Hines JD, Lutterbaugh J, Myeroff L, Mackay W, Gordon N, Rustum Y, Luna E, Kleinerman J. Mutant K-ras oncogenes in colon cancers Do not predict Patient's chemotherapy response or survival. Clin Cancer Res. 1995;1(4):441-445.

    Not in our library

55. 55.

    Mayer A., Takimoto M., Fritz E., Schellander G., Kofler K., Ludwig H. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer. 1993;71(8):2454-2460.

    Not in our library10.1002/1097-0142(19930415)71:8<2454::aid-cncr2820710805>3.0.co;2-2

56. 56.

    McArdle C. S., Hole D. Impact of variability among surgeons on postoperative morbidity and mortality and ultimate survival. BMJ. 1991;302(6791):1501-1505.

    Not in our library10.1136/bmj.302.6791.1501

57. 57.

    Miller F., Heimann T. M., Quish A., Pyo D. J., Szporn A., Martinelli G., Fasy T. M. ras and c-myc protein expression in colorectal carcinoma. Study of cancer-prone patients. Dis Colon Rectum. 1992;35(5):430-435.

    Not in our library10.1007/bf02049398

58. 58.

    Miyahara M., Saito T., Kaketani K., Sato K., Kuwahara A., Shimoda K., Kobayashi M. Clinical significance of ras p21 overexpression for patients with an advanced colorectal cancer. Dis Colon Rectum. 1991;34(12):1097-1102.

    Not in our library10.1007/bf02050069

59. 59.

    Moertel C. G., Fleming T. R., Macdonald J. S., Haller D. G., Laurie J. A., Tangen C. M., Ungerleider J. S., Emerson W. A., Tormey D. C., Glick J. H. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med. 1995;122(5):321-326.

    Not in our library10.7326/0003-4819-122-5-199503010-00001

60. 60.

    Mulcahy H. E., Duffy M. J., Gibbons D., McCarthy P., Parfrey N. A., O'Donoghue D. P., Sheahan K. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet. 1994;344(8922):583-584.

    Not in our library10.1016/s0140-6736(94)91968-2

61. 61.

    Mulder J. W., Kruyt P. M., Sewnath M., Oosting J., Seldenrijk C. A., Weidema W. F., Offerhaus G. J., Pals S. T. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet. 1994;344(8935):1470-1472.

    Not in our library10.1016/s0140-6736(94)90290-9

62. 62.

    Murray G. I., Duncan M. E., O'Neil P., Melvin W. T., Fothergill J. E. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med. 1996;2(4):461-462.

    Not in our library10.1038/nm0496–461

63. 63.

    Nagai M. A., Habr-Gama A., Oshima C. T., Brentani M. M. Association of genetic alterations of c-myc, c-fos, and c-Ha-ras proto-oncogenes in colorectal tumors. Frequency and clinical significance. Dis Colon Rectum. 1992;35(5):444-451.

    Not in our library10.1007/bf02049400

64. 64.

    Nakamori S., Kameyama M., Imaoka S., Furukawa H., Ishikawa O., Sasaki Y., Kabuto T., Iwanaga T., Matsushita Y., Irimura T. Increased expression of sialyl Lewisx antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res. 1993;53(15):3632-3637.

    Not in our library

65. 65.

    Neoptolemos J. P., Oates G. D., Newbold K. M., Robson A. M., McConkey C., Powell J. Cyclin/proliferation cell nuclear antigen immunohistochemistry does not improve the prognostic power of Dukes' or Jass' classifications for colorectal cancer. Br J Surg. 1995;82(2):184-187.

    Not in our library10.1002/bjs.1800820214

66. 66.

    Ofner D., Riehemann K., Maier H., Riedmann B., Nehoda H., Tötsch M., Böcker W., Jasani B., Schmid K. W. Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br J Cancer. 1995;72(4):981-985.

    Not in our library10.1038/bjc.1995.446

67. 67.

    Ogunbiyi O. A., Goodfellow P. J., Gagliardi G., Swanson P. E., Birnbaum E. H., Fleshman J. W., Kodner I. J., Moley J. F. Prognostic value of chromosome 1p allelic loss in colon cancer. Gastroenterology. 1997;113(3):761-766.

    Not in our library10.1016/s0016-5085(97)70169-0

68. 68.

    Ogunbiyi O. A., Goodfellow P. J., Herfarth K., Gagliardi G., Swanson P. E., Birnbaum E. H., Read T. E., Fleshman J. W., Kodner I. J., Moley J. F. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol. 1998;16(2):427-433.

    Not in our library10.1200/jco.1998.16.2.427

69. 69.

    Paradiso A., Rabinovich M., Vallejo C., Machiavelli M., Romero A., Perez J., Lacava J., Cuevas M. A., Rodriquez R., Leone B. p53 and PCNA expression in advanced colorectal cancer: response to chemotherapy and long-term prognosis. Int J Cancer. 1996;69(6):437-441.

    Not in our library10.1002/(sici)1097-0215(19961220)69:6<437::aid-ijc2>3.0.co;2-5

70. 70.

    Parkin D. M., Pisani P., Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer. 1993;54(4):594-606.

    Not in our library10.1002/ijc.2910540413

71. 71.

    Poller D. N., Baxter K. J., Shepherd N. A. p53 and Rb1 protein expression: are they prognostically useful in colorectal cancer? Br J Cancer. 1997;75(1):87-93.

    Not in our library10.1038/bjc.1997.14

72. 72.

    Pricolo V. E., Finkelstein S. D., Wu T. T., Keller G., Bakker A., Swalsky P. A., Bland K. I. Prognostic value of TP53 and K-ras-2 mutational analysis in stage III carcinoma of the colon. Am J Surg. 1996;171(1):41-46.

    Not in our library10.1016/s0002-9610(99)80071-3

73. 73.

    Reinbach D. H., McGregor J. R., Murray G. D., O'Dwyer P. J. Effect of the surgeon's specialty interest on the type of resection performed for colorectal cancer. Dis Colon Rectum. 1994;37(10):1020-1023.

    Not in our library10.1007/bf02049316

74. 74.

    Robson H., Anderson E., James R. D., Schofield P. F. Transforming growth factor beta 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients. Br J Cancer. 1996;74(5):753-758.

    Not in our library10.1038/bjc.1996.432

75. 75.

    Schneider H. J., Sampson S. A., Cunningham D., Norman A. R., Andreyev H. J., Tilsed J. V., Clarke P. A. Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas. Br J Cancer. 1997;75(3):427-431.

    Not in our library10.1038/bjc.1997.70

76. 76.

    Schumacher U., Higgs D., Loizidou M., Pickering R., Leathem A., Taylor I. Helix pomatia agglutinin binding is a useful prognostic indicator in colorectal carcinoma. Cancer. 1994;74(12):3104-3107.

    Not in our library10.1002/1097-0142(19941215)74:12<3104::aid-cncr2820741207>3.0.co;2-0

77. 77.

    Shibata D., Reale M. A., Lavin P., Silverman M., Fearon E. R., Steele G., Jessup J. M., Loda M., Summerhayes I. C. The DCC protein and prognosis in colorectal cancer. N Engl J Med. 1996;335(23):1727-1732.

    Not in our library10.1056/nejm199612053352303

78. 78.

    Sinicrope F. A., Hart J., Michelassi F., Lee J. J. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res. 1995;1(10):1103-1110.

    Not in our library

79. 79.

    Smith D. R., Goh H. S. Overexpression of the c-myc proto-oncogene in colorectal carcinoma is associated with a reduced mortality that is abrogated by point mutation of the p53 tumor suppressor gene. Clin Cancer Res. 1996;2(6):1049-1053.

    Not in our library

80. 80.

    Soong R., Grieu F., Robbins P., Dix B., Chen D., Parsons R., House A., Iacopetta B. p53 alterations are associated with improved prognosis in distal colonic carcinomas. Clin Cancer Res. 1997;3(8):1405-1411.

    Not in our library

81. 81.

    Span M., Moerkerk P. T., De Goeij A. F., Arends J. W. A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients. Int J Cancer. 1996;69(3):241-245.

    Not in our library10.1002/(sici)1097-0215(19960621)69:3<241::aid-ijc15>3.0.co;2-a

82. 82.

    Spitz F. R., Giacco G. G., Hess K., Larry L., Rich T. A., Janjan N., Cleary K. R., Skibber J. M. p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer. Clin Cancer Res. 1997;3(10):1685-1690.

    Not in our library

83. 83.

    Sun X. F., Carstensen J. M., Stål O., Zhang H., Nordenskjöld B. Proliferating cell nuclear antigen (PCNA) in relation to ras, c-erbB-2,p53, clinico-pathological variables and prognosis in colorectal adenocarcinoma. Int J Cancer. 1996;69(1):5-8.

    Not in our library10.1002/(sici)1097-0215(19960220)69:1<5::aid-ijc2>3.0.co;2-8

84. 84.

    Sun X. F., Carstensen J. M., Stål O., Zhang H., Nordenskjöld B. c-erbB-2 oncoprotein in relation to DNA ploidy and prognosis in colorectal adenocarcinoma. APMIS. 1995;103(4):309-315.

    Not in our library10.1111/j.1699-0463.1995.tb01112.x

85. 85.

    Sun X. F., Carstensen J. M., Zhang H., Stål O., Wingren S., Hatschek T., Nordenskjöld B. Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet. 1992;340(8832):1369-1373.

    Not in our library10.1016/0140-6736(92)92558-w

86. 86.

    Sun X. F., Wingren S., Carstensen J. M., Stål O., Hatschek T., Boeryd B., Nordenskjöld B., Zhang H. ras p21 expression in relation to DNA ploidy, S-phase fraction and prognosis in colorectal adenocarcinoma. Eur J Cancer. 1991;27(12):1646-1649.

    Not in our library10.1016/0277-5379(91)90437-i

87. 87.

    Takahashi Y., Tucker S. L., Kitadai Y., Koura A. N., Bucana C. D., Cleary K. R., Ellis L. M. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg. 1997;132(5):541-546.

    Not in our library10.1001/archsurg.1997.01430290087018

88. 88.

    Takebayashi Y., Akiyama S., Akiba S., Yamada K., Miyadera K., Sumizawa T., Yamada Y., Murata F., Aikou T. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst. 1996;88(16):1110-1117.

    Not in our library10.1093/jnci/88.16.1110

89. 89.

    Wadler S., Bajaj R., Neuberg D., Agarwal V., Haynes H., Benson A. B. Prognostic implications of c-Ki-ras2 mutations in patients with advanced colorectal cancer treated with 5-fluorouracil and interferon: a study of the eastern cooperative oncology group (EST 2292). Cancer J Sci Am. 1997;3(5):284-288.

    Not in our library

90. 90.

    Witzig T. E., Loprinzi C. L., Gonchoroff N. J., Reiman H. M., Cha S. S., Wieand H. S., Katzmann J. A., Paulsen J. K., Moertel C. G. DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma. Cancer. 1991;68(4):879-888.

    Not in our library10.1002/1097-0142(19910815)68:4<879::aid-cncr2820680434>3.0.co;2-4

91. 91.

    Wolmark N., Wieand H. S., Rockette H. E., Fisher B., Glass A., Lawrence W., Lerner H., Cruz A. B., Volk H., Shibata H. The prognostic significance of tumor location and bowel obstruction in Dukes B and C colorectal cancer. Findings from the NSABP clinical trials. Ann Surg. 1983;198(6):743-752.

    Not in our library10.1097/00000658-198312000-00013

92. 92.

    Wynford-Thomas D. P53 in tumour pathology: can we trust immunocytochemistry? J Pathol. 1992;166(4):329-330.

    Not in our library10.1002/path.1711660402

93. 93.

    Yamaguchi A., Nakagawara G., Kurosaka Y., Nishimura G., Yonemura Y., Miyazaki I. p53 immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance. Br J Cancer. 1993;68(2):399-402.

    Not in our library10.1038/bjc.1993.348

94. 94.

    Yamaguchi A., Urano T., Goi T., Saito M., Takeuchi K., Hirose K., Nakagawara G., Shiku H., Furukawa K. Expression of a CD44 variant containing exons 8 to 10 is a useful independent factor for the prediction of prognosis in colorectal cancer patients. J Clin Oncol. 1996;14(4):1122-1127.

    Not in our library10.1200/jco.1996.14.4.1122

95. 95.

    Younes M., Fernandez L., Lechago J. Transforming growth factor alpha (TGF-alpha) expression in biopsies of colorectal carcinoma is a significant prognostic indicator. Anticancer Res. 1996;16(4A):1999-2003.

    Not in our library

96. 96.

    Zeng Z. S., Huang Y., Cohen A. M., Guillem J. G. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol. 1996;14(12):3133-3140.

    Not in our library10.1200/jco.1996.14.12.3133

97. 97.

    Zeng Z. S., Sarkis A. S., Zhang Z. F., Klimstra D. S., Charytonowicz E., Guillem J. G., Cordon-Cardo C., Cohen A. M. p53 nuclear overexpression: an independent predictor of survival in lymph node--positive colorectal cancer patients. J Clin Oncol. 1994;12(10):2043-2050.

    Not in our library10.1200/jco.1994.12.10.2043

Cited by papers we hold 1

• MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance · 2016
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.